One Patient, One Arm, Zero Immunosuppression: The Diabetes Experiment That Won't Quit
A single Type 1 diabetes patient has been producing their own insulin for 14 months after receiving engineered cells in their forearm, with zero immunosuppressive drugs. Sana Biotechnology's tiny experiment could reshape the race for a diabetes cure.
Imagine getting a shot in your arm that teaches your body to make insulin again. No daily injections. No immune-suppressing drugs. No devices strapped to your body. Just your own transplanted cells, quietly doing the job your pancreas gave up on years ago.
That's the premise behind Sana Biotechnology's experimental cell therapy for Type 1 diabetes. And 14 months into the first-ever human test, it's still working.
A Forearm That Makes Insulin
Sana's therapy, called UP421, takes donor-derived pancreatic islet cells (the tiny clusters that produce insulin) and genetically engineers them to hide from the immune system. Think of it like giving cells a cloaking device. Normally, your body treats transplanted cells like intruders and attacks them on sight. Sana's "hypoimmune" technology strips away the molecular ID badges, called HLA markers, that the immune system uses to spot foreign cells.
The result: cells that can survive inside a patient's body without the cocktail of immunosuppressive drugs that usually comes with any transplant.
In this first-in-human study at Uppsala University Hospital in Sweden, a single patient with Type 1 diabetes received UP421 injected directly into their forearm muscle. No immunosuppression. No encapsulation device. Just engineered cells, dropped into a muscle, left to fend for themselves.
Fourteen months later, those cells are still alive and producing insulin.
The Numbers That Matter
Before the transplant, the patient had undetectable C-peptide, a blood marker that indicates your body is making its own insulin. If C-peptide is at zero, your beta cells are essentially dead or gone. That's the hallmark of Type 1 diabetes.
At 14 months, both fasting and meal-stimulated C-peptide levels were still measurable. They were comparable to levels seen at six months and actually higher than levels at nine and twelve months. Even more encouraging: when the patient ate a mixed meal, C-peptide rose appropriately, mimicking the way a healthy pancreas responds to food.
A PET-MRI scan at 12 weeks confirmed the transplanted islet cells were still physically present at the forearm site. No safety concerns have been reported through the entire 14-month period.
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
